Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.51 |
| ▸ | CNR2 | P34972 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879470 | 0.89 | S1PR1 (0.49) | S1PR1CNR2MAOAMAOBRXFP1 | |
| SCHEMBL3888689 | 0.88 | S1PR1 (0.59) | S1PR1CNR2ALDH1A1GLAMAOA | |
| SCHEMBL3879645 | 0.88 | CNR2 (0.52) | CNR2MAOAMAOBRXFP1TP53 | |
| SCHEMBL3946711 | 0.85 | S1PR1 (0.50) | S1PR1CNR2ALDH1A1GLAMAOA | |
| SCHEMBL14322622 | 0.81 | S1PR1 (0.75) | S1PR1CNR2MAOB | |
| SCHEMBL3879592 | 0.81 | TP53 (0.55) | CNR2MAOAMAOBRXFP1TP53 | |
| SCHEMBL3886775 | 0.78 | TP53 (0.52) | CNR2MAOAMAOBRXFP1TP53 | |
| SCHEMBL3947207 | 0.77 | CNR2 (0.49) | S1PR1CNR2MAOAMAOBRXFP1 | |
| SCHEMBL4522127 | 0.77 | CNR2 (0.49) | S1PR1CNR2MAOAMAOBRXFP1 | |
| SCHEMBL3947213 | 0.77 | CNR2 (0.49) | S1PR1CNR2MAOAMAOBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318546-A1 | Chromen-2-One Derivatives | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318546-A1 | Chromen-2-One Derivatives | CYP1A2, CYP4B1, CYP1B1 | S1PR1 3084/4885CNR2 538/4885ALDH1A1 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.